Comparative Pharmacology
Head-to-head clinical analysis: ELAHERE versus POLIVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAHERE versus POLIVY.
ELAHERE vs POLIVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). It consists of a humanized anti-FRα antibody conjugated to the maytansinoid DM4, a microtubule inhibitor. Upon binding to FRα on tumor cells, the ADC is internalized and releases DM4, which binds to tubulin and disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis.
Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.
6 mg/kg adjusted ideal body weight intravenously every 3 weeks until disease progression or unacceptable toxicity.
1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.
None Documented
None Documented
Terminal half-life approximately 6.2 days (range 3.7-9.5 days) after IV administration; supports every-3-week dosing interval.
The terminal elimination half-life of polatuzumab vedotin is approximately 12 days (range 8–20 days) for the antibody-drug conjugate. This supports a dosing interval of every 3 weeks. The half-life may be prolonged in patients with severe hepatic impairment.
Fecal (approximately 80%) as unchanged drug; renal (approximately 8%) as unchanged drug and metabolites.
Polivy (polatuzumab vedotin) is eliminated primarily through catabolism into small peptides and amino acids. The antibody-drug conjugate is not significantly excreted renally as intact compound; approximately <1% of the dose is excreted unchanged in urine. The majority of the drug is metabolized and eliminated via biliary/fecal routes, with approximately 80% of the total dose recovered in feces over 3 weeks, primarily as metabolites.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent